Results 241 to 250 of about 19,378,005 (296)

The role of neuroimaging in neurotoxicity after chimeric antigen receptor T-cell therapy. [PDF]

open access: yesTher Adv Neurol Disord
Lasocki A   +3 more
europepmc   +1 more source

Independent validation of the International Metabolic Prognostic Index (CAR‐IMPI) in patients with aggressive diffuse large B‐cell lymphoma treated with CAR‐T

open access: yes
British Journal of Haematology, EarlyView.
Eugenio Galli   +11 more
wiley   +1 more source

Outcomes for post‐transplant relapsed acute lymphoblastic leukaemia in the era of novel therapies: A retrospective multicentre UK study

open access: yes
British Journal of Haematology, EarlyView.
Alexandros Rampotas   +16 more
wiley   +1 more source

Reduced‐dose pegylated asparaginase reliably achieves therapeutic levels in adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma

open access: yes
British Journal of Haematology, EarlyView.
Leah A. Goldberg   +14 more
wiley   +1 more source

Advances in chimeric antigen receptor T cells

Current Opinion in Hematology, 2020
Purpose of review To discuss the important advances in CAR T cell therapy over the past year, focusing on clinical results where available. Recent findings Approximately 30 years after they were first conceived of and 15 years after the first small-scale single-center clinical ...
Ofrat, Beyar-Katz, Saar, Gill
openaire   +2 more sources

Chimeric antigen receptor T-cell toxicity

Current Opinion in Pediatrics, 2019
Purpose of review Chimeric antigen receptor -(CAR) T-cell therapy has become a commonly used immunotherapy originally used in the treatment of B-cell leukemias but which are now applied broadly across tumor classes. Although high rates of remission are associated with CAR T-cell therapy, toxicities associated with these novel ...
DaMarcus E, Baymon, Edward W, Boyer
openaire   +2 more sources

Chimeric antigen receptor T cells march into T cell malignancies

Journal of Cancer Research and Clinical Oncology, 2023
T cell malignancies represent a diverse collection of leukemia/lymphoma conditions in humans arising from aberrant T cells. Such malignancies are often associated with poor clinical prognoses, cancer relapse, as well as progressive resistance to anti-cancer treatments.
Jie, Tang, Xudong, Zhao
openaire   +2 more sources

Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas

Hematology/Oncology Clinics of North America, 2023
The authors review the current use of chimeric antigen receptor (CAR)-transduced T cells (CAR-T) in Hodgkin lymphoma (HL) and T-cell lymphomas (TCL) and discuss the data on CD30-targeting CAR-T cells, which seem to be safe and effective in HL. In addition, the authors examine the use of CAR-T cells targeting CD30, CD5, or CD7 in TCL, while highlighting
Muhsen, Ibrahim N   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy